Conclusions and Relevance Cannabinoid drugs may prevent the onset of pain by producing small increases in pain thresholds but may not reduce the intensity of experimental pain already being experienced ; instead , cannabinoids may make experimental pain feel less unpleasant and more tolerable , suggesting an influence on affective processes .
Cannabis-induced improvements in pain-related negative affect may underlie the widely held belief that cannabis relieves pain
Importance Cannabinoid drugs are widely used as analgesics , but experimental pain studies have produced mixed findings .
The analgesic properties of cannabinoids remain unclear .
Objective To conduct a systematic review and meta- analysis of the association between cannabinoid drug administration and experimental pain outcomes in studies of healthy adults .
Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews
Medicinal cannabis has already entered mainstream medicine in some countries . This systematic review ( SR ) aim ed at evaluating the efficacy , acceptability and safety of cannabis-based medicines for chronic pain management . Qualitative systematic review of SRs of r and omized controlled trials with cannabis-based medicines for chronic pain management . The Cochrane data bases of SRs , Data base of Abstract s of Review s of Effects and PubMed were search ed for SR published in the period January 2009 to January 2017 . Assessment of the method ological quality of SR was performed by the AMSTAR checklist . Out of 748 papers identified , 10 SRs met the inclusion criteria . The method ological quality was high in four and moderate in six SRs . There were inconsistent findings of four SRs on the efficacy of cannabis-based medicines in neuropathic pain and of one SR for painful spasms in multiple sclerosis . There were consistent results that there was insufficient evidence of any cannabis-based medicine for pain management in patients with rheumatic diseases ( three SRs ) and in cancer pain ( two SRs ) . Cannabis-based medicines undoubtedly enrich the possibilities of drug treatment of chronic pain conditions . It remains the responsibility of the health care community to continue to pursue rigorous study of cannabis-based medicines to provide evidence that meets the st and ard of 21st century clinical care . SIGNIFICANCE We provide an overview of systematic review s on the efficacy , tolerability and safety of cannabis-based medicines for chronic pain management . There are inconsistent findings of the efficacy of cannabinoids in neuropathic pain and painful spasms in multiple sclerosis . There are inconsistent results on tolerability and safety of cannabis-based medicines for any chronic pain
Conclusions and Relevance Cannabinoid drugs may prevent the onset of pain by producing small increases in pain thresholds but may not reduce the intensity of experimental pain already being experienced ; instead , cannabinoids may make experimental pain feel less unpleasant and more tolerable , suggesting an influence on affective processes .
Cannabis-induced improvements in pain-related negative affect may underlie the widely held belief that cannabis relieves pain
Importance Cannabinoid drugs are widely used as analgesics , but experimental pain studies have produced mixed findings .
The analgesic properties of cannabinoids remain unclear .
Objective To conduct a systematic review and meta- analysis of the association between cannabinoid drug administration and experimental pain outcomes in studies of healthy adults .